2019
Higher urinary cortisol levels associate with increased cardiovascular risk
Haas AV, Hopkins PN, Brown NJ, Pojoga LH, Williams JS, Adler GK, Williams GH. Higher urinary cortisol levels associate with increased cardiovascular risk. Endocrine Connections 2019, 8: 634-640. PMID: 31018177, PMCID: PMC6528405, DOI: 10.1530/ec-19-0182.Peer-Reviewed Original ResearchFramingham risk scoreCardiovascular riskRisk allele carriersRisk scoreAllele carriersCortisol groupCortisol levelsHigher urinary cortisol levelsUrine free cortisolNon-risk allele carriersNon-diabetic individualsBlood pressure measurementsCross-sectional studyRisk allele statusUrinary cortisol levelsIndependent predictorsUrinary cortisolBlood samplesDiscordant findingsLarger sample sizeMultivariate analysisAllele statusCortisol collectionRisk allelesSample size
2018
Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis
Kaseda R, Tsuchida Y, Gamboa JL, Zhong J, Zhang L, Yang H, Dikalova A, Bian A, Davies S, Fogo AF, Linton MF, Brown NJ, Ikizler TA, Kon V. Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis. Nutrition Metabolism And Cardiovascular Diseases 2018, 28: 582-591. PMID: 29691148, PMCID: PMC5959764, DOI: 10.1016/j.numecd.2018.02.020.Peer-Reviewed Original ResearchConceptsAngiotensin receptor blockersHigh-density lipoproteinToll-like receptorsAnti-inflammatory effectsReceptor blockersCytokine responsesActivation of TLRsSerum amyloid A (SAA) levelsACE inhibitor effectsHigh cardiovascular riskAdvanced kidney diseaseMaintenance hemodialysis patientsInflammatory cytokine responseAnti-oxidative effectsACEI treatmentAtheroprotective actionARB treatmentCardiovascular eventsMaintenance hemodialysisAngiotensin actionCardiovascular riskHemodialysis patientsCellular superoxide productionHDL functionalityKidney disease
2012
Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies
Brown NJ. Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. International Journal Of Cardiology Cardiovascular Risk And Prevention 2012, 6: 163-168. PMID: 22433315, PMCID: PMC3422131, DOI: 10.1016/j.jash.2012.02.003.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1Cardiovascular eventsDipeptidyl peptidase IV inhibitorsAntidiabetic agentsPeptidase IV inhibitorsBlood pressureClinical trialsPeptide-1Animal modelsType 2 diabetes mellitusIncretin-based agentsBlood pressure effectsIncretin-based therapiesIV inhibitorsLarge clinical trialsFavorable effectIschemia/reperfusionTight glucose controlOverweight diabeticsCardiovascular effectsCardiovascular riskDiabetes mellitusIntensive therapyGlucose controlThiazolidinedione rosiglitazone
2010
Increased Sensitivity to Angiotensin II Is Present Postpartum in Women With a History of Hypertensive Pregnancy
Saxena AR, Karumanchi SA, Brown NJ, Royle CM, McElrath TF, Seely EW. Increased Sensitivity to Angiotensin II Is Present Postpartum in Women With a History of Hypertensive Pregnancy. Hypertension 2010, 55: 1239-1245. PMID: 20308605, PMCID: PMC2880505, DOI: 10.1161/hypertensionaha.109.147595.Peer-Reviewed Original ResearchConceptsLow-sodium balanceSoluble fms-like tyrosine kinase-1 levelsHypertensive pregnanciesDiastolic blood pressureAngiotensin IIBlood pressurePressor responseHigh sodium balanceInfused angiotensin IISystolic pressor responseNew-onset hypertensionAngiotensin II infusionFuture cardiovascular riskHigh-salt dietSystolic blood pressureII infusionCardiovascular riskNormotensive pregnanciesPostpartum womenSodium balancePregnancySalt loadingPostpartumDietary phasesWomen
1997
Plasminogen actiwator inhibitor type 1 in diabetes and hypertension
Litchfield W, Brown N, Vaughan D. Plasminogen actiwator inhibitor type 1 in diabetes and hypertension. Current Opinion In Endocrinology Diabetes And Obesity 1997, 4: 233-238. DOI: 10.1097/00060793-199706000-00009.Peer-Reviewed Original ResearchCardiovascular riskPAI-1Inhibitor type 1Type 1Elevated levelsIncreased cardiovascular riskRenin-angiotensin systemEndogenous fibrinolytic systemPlasminogen activator inhibitor type 1Activator inhibitor type 1Tissue plasminogen activatorHypertensive patientsEssential hypertensionMyocardial infarctionCardiovascular diseaseFibrinolytic systemHypertensionPlasminogen activatorStrong associationIncidenceRiskPrimary inhibitorHyperinsulinemiaHypertriglyceridemiaInfarction